Prothena(PRTA) - 2025 Q4 - Annual Report

Pipeline and Therapeutic Development - Prothena's pipeline includes therapeutic candidates for diseases such as Parkinson's disease, ATTR amyloidosis, Alzheimer's disease, and ALS, leveraging proprietary CYTOPE® technology[20] - The company is currently advancing four therapeutic antibody programs in active clinical development, including prasinezumab for Parkinson's disease and coramitug for ATTR amyloidosis[42] - Prasinezumab is being evaluated in the Phase 3 PARAISO clinical trial, while coramitug is in the Phase 3 CLEOPATTRA clinical trial, both in collaboration with major pharmaceutical partners[25] - Prothena has received FDA clearance for an investigational new drug application for PRX123, an Alzheimer's disease vaccine program, which has also been granted Fast Track designation[43] - The company is focusing on diseases that lack effective therapies, particularly in neurodegenerative and rare peripheral amyloid diseases[33] - Prothena's diverse pipeline includes antibody, small molecule, and vaccine approaches, positioning it to impact a broad spectrum of diseases[43] - Prothena's research includes the development of an anti-pTDP-43 CYTOPE for ALS, addressing the core molecular pathology associated with the disease[36] Clinical Trials and Results - Prasinezumab is currently in Phase 3 PARAISO trial for early Parkinson's disease, with approximately 900 participants enrolled[49] - In the Phase 2b PADOVA trial, prasinezumab showed a hazard ratio (HR) of 0.84 for time to confirmed motor progression, with a nominal p-value of 0.0657[50] - The Phase 2 PASADENA trial indicated a 35% reduction in motor function decline for prasinezumab-treated patients compared to placebo after one year[54] - In the Phase 1 clinical trials, prasinezumab demonstrated a mean concentration of 0.3% in cerebrospinal fluid relative to serum, exceeding expectations[59] - The ongoing Phase 3 trial aims to evaluate the efficacy and safety of prasinezumab over a minimum of 104 weeks[49] - The Phase 2b PADOVA trial included 586 participants treated for a minimum of 18 months, showing significant effects in a subgroup treated with levodopa (HR=0.79, nominal p=0.0431)[50] - The Phase 2 PASADENA trial's primary endpoint was the change in MDS-UPDRS total score at 52 weeks, with pooled dose levels showing a reduction of 14.0%[55] - Prasinezumab was found to be generally safe and well tolerated, with most adverse events reported as mild or moderate[58] - The Phase 2 trial of coramitug showed a statistically significant reduction in NT-proBNP levels by 48% compared to placebo over 52 weeks[76] - The Phase 3 CLEOPATTRA trial for coramitug is set to evaluate approximately 1,280 participants with ATTR-CM, focusing on cardiovascular deaths and events over a four-year period[75] Collaborations and Partnerships - The company is collaborating with Roche for the development of prasinezumab, focusing on its potential in treating synucleinopathies[45] - Prothena has earned $135.0 million of a total $755.0 million in potential clinical, regulatory, and sales milestones from Roche, including $30.0 million upfront and $60.0 million for the PADOVA trial initiation[63] - The Phase 2 clinical trial of prasinezumab in early Parkinson's disease, PADOVA, began in May 2021, triggering a $60.0 million milestone payment from Roche[61] - Coramitug, an investigational antibody for ATTR amyloidosis, has a potential total milestone payment structure of up to $290.0 million for development and regulatory achievements, plus tiered royalties based on annual net sales[67] - In July 2023, the company entered into an exclusive global license agreement for BMS-986446, receiving an option exercise fee of $55 million and being eligible for up to $563 million in regulatory and sales milestone payments[87] - The company is developing PRX123, a dual vaccine targeting both Aβ and tau proteins, with preclinical studies showing promising immune responses against both targets[103] - The company plans to explore partnership opportunities to advance PRX012 and the preclinical PRX012-TfR antibody programs[97] Financial Performance and Capital Requirements - The company incurred net losses of $244.1 million, $122.3 million, and $147.0 million for the years ended December 31, 2025, 2024, and 2023, respectively, with an accumulated deficit of $1.3 billion as of December 31, 2025[151] - As of December 31, 2025, the company had cash and cash equivalents of $307.5 million, which is expected to be sufficient to meet obligations for at least the next twelve months[153] - The company anticipates requiring additional capital to continue research and development and eventual commercialization of drug candidates, with future capital requirements dependent on various unknown factors[157] - The company may need to raise substantial additional funds through public or private equity or debt financings, which could result in dilution to existing shareholders or unfavorable terms[157] Regulatory and Compliance Challenges - The regulatory approval process for drug candidates is lengthy and unpredictable, typically taking many years, and there is no guarantee of approval for any existing or future candidates[196] - If regulatory approval is obtained, it may be for fewer indications than requested, which could limit the commercial prospects of the drug candidates[198] - Ongoing regulatory requirements must be met post-approval, and failure to comply could result in sanctions or suspension of product sales[202] - The acceptance of clinical trial data from international studies by the FDA or other regulatory authorities may be subject to strict conditions, potentially leading to additional trials[200] - Adverse side effects identified during development or post-approval could necessitate further trials or product withdrawals, significantly impacting revenue generation[204] - Regulatory compliance is critical, as failure to adhere to healthcare laws can result in legal actions, fines, and delays in product approvals[127] Operational Risks and Workforce Management - The company is dependent on third-party manufacturers for clinical supplies of its drug candidates, including collaborations with Roche and Novo Nordisk[139][140] - The company faces significant competition from larger pharmaceutical companies and generic drug manufacturers, which may adversely affect its revenues and results[136][138] - The company is highly dependent on key personnel, including the President and CEO, and the loss of such personnel could impede research and development objectives[159] - The company announced a 63% reduction in workforce in June 2025 to lower operating costs and support remaining programs and business development activities[107] - The company expects to reduce its headcount by 17 employees in 2026, primarily in research and development roles[143] Cybersecurity and Data Protection - Cybersecurity risks are increasing, and breaches of information technology systems could disrupt development programs and business operations[165] - Changes in privacy and data protection laws may increase compliance costs and expose the company to liability, impacting business operations and financial performance[168] - Compliance with privacy and data security laws is a rigorous process that may increase operational and compliance costs, potentially impacting business practices[169] - The EU GDPR imposes fines for breaches up to €20 million or 4% of total annual global turnover, which could significantly affect the company's financial condition[172] - The UK GDPR has similar penalties, with fines up to £17.5 million or 4% of total annual global turnover, indicating substantial compliance costs[173]